文献速递消化系统肿瘤

PANOPTIMOX-PRODIGE 35随机II期试验:转移性胰腺癌一线两种序贯治疗评估

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.
PubMed 文献 · J Clin Oncol · 2021-07-21

该随机II期试验纳入276例转移性胰腺癌患者,比较6个月FOLFIRINOX(A组)、4个月FOLFIRINOX后亚叶酸钙加氟尿嘧啶维持(B组)及吉西他滨与FOLFIRI每2个月交替序贯(C组)。主要终点6个月无进展生存率分别为47.1%、42.9%和34.1%,中位总生存分别为10.1、11.2和7.3个月。结论认为4个月FOLFIRINOX诱导后疾病控制者采用亚叶酸钙加氟尿嘧啶维持可行且有效。

要点

  • 4个月FOLFIRINOX后亚叶酸钙加氟尿嘧啶维持治疗在转移性胰腺癌中可行且有效。
  • 维持组中位无生活质量恶化生存期11.4个月,优于A组7.2个月和C组7.5个月。
  • 维持组3/4级神经毒性19.8%,高于A组10.2%,可能与奥沙利铂累积剂量更高有关。

核心结论

  • 在转移性胰腺癌患者中,4个月FOLFIRINOX诱导化疗后疾病控制者接受亚叶酸钙加氟尿嘧啶维持治疗可行且有效。

研究设计与样本

  • 随机II期研究,2015年1月至2016年11月纳入276例转移性胰腺癌患者,平均年龄63岁(范围40-76岁),随机分入A组91例、B组92例、C组90例。
  • A组接受6个月FOLFIRINOX;B组接受4个月FOLFIRINOX后对疾病控制者给予亚叶酸钙加氟尿嘧啶维持;C组接受吉西他滨与氟尿嘧啶、亚叶酸钙、伊立替康每2个月交替序贯治疗。
  • 主要终点为6个月无进展生存率。

主要发现

  • 6个月无进展生存率A组47.1%、B组42.9%、C组34.1%。
  • 中位总生存A组10.1个月、B组11.2个月、C组7.3个月。
  • 3/4级神经毒性A组10.2%、B组19.8%;奥沙利铂实际接受剂量/目标剂量中位比值A组83%、B组92%。
  • 无生活质量评分恶化中位生存期维持组11.4个月,A组7.2个月,C组7.5个月。

临床怎么用

  • 对4个月FOLFIRINOX诱导后疾病控制的转移性胰腺癌患者,可考虑亚叶酸钙加氟尿嘧啶维持治疗以延长无生活质量恶化生存。
  • 维持治疗期间需关注奥沙利铂累积剂量相关的严重神经毒性增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4-ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over gemcitabine for overall survival. The high limiting oxaliplatin-related neurotoxicity supports the evaluation of an oxaliplatin stop-and-go strategy and a sequential strategy in mPC. METHODS: In this phase II study, patients were randomly assigned to receive either 6 months of FOLFIRINOX (arm A), 4 months of FOLFIRINOX followed by leucovorin plus fluorouracil maintenance treatment for controlled patients (arm B), or a sequential treatment alternating gemcitabine and fluorouracil, leucovorin, and irinotecan every 2 months (arm C). The primary end point was progression-free survival at 6 months. RESULTS: Between January 2015 and November 2016, 276 patients (mean age: 63 years; range: 40-76 years) were enrolled (A: 91, B: 92, and C: 90). Grade 3 or 4 neurotoxicity occurred in 10.2% of patients in arm A and 19.8% in arm B. The median ratio of received dose/targeted dose of oxaliplatin was 83% in arm A and 92% in arm B. The 6-month progression-free survival was 47.1% in A, 42.9% in B, and 34.1% in C. The median overall survival was 10.1 months in arm A, 11.2 in arm B, and 7.3 in arm C. Median survival without deterioration in quality-of-life scores was higher in the maintenance arm (11.4 months) than in arms A and C (7.2 and 7.5 months, respectively). CONCLUSION: Maintenance with leucovorin plus fluorouracil appears to be feasible and effective in patients with mPC controlled after 4 months of induction chemotherapy with FOLFIRINOX. Severe neurotoxicity was higher in the maintenance therapy arm, probably because of the higher cumulative dose of oxaliplatin.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dahan L, Williet N, Le Malicot K, et al. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. J Clin Oncol. 2021. PMID: 34288696. doi:10.1200/JCO.20.03329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。